SNWVHealthcare · Medical DevicesTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores SANUWAVE Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (100): The business earns solid, repeatable profits on what it owns.
Momentum (2): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SNWV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Mar 2026 | Roth Capital | Reiterates | Buy | $53 → $47 |
| 3 Sept 2025 | Northland Capital Markets | Initiates | Outperform | — |
| 22 Aug 2025 | Roth Capital | Maintains | Buy | — |
| 29 July 2025 | Roth Capital | Initiates | Buy | — |
| 15 Sept 2020 | Lake Street | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SNWV appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 66% of US stocks
Cheaper than 72% of US stocks
Cheaper than 5% of US stocks
Cheaper than 32% of US stocks
Higher than 22% of US stocks
Higher than 31% of US stocks
Higher than 88% of US stocks
Higher than 29% of US stocks
Higher than 92% of US stocks
Higher than 99% of US stocks
Higher than 79% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own SANUWAVE Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published the transcript of SANUWAVE Health, Inc.'s Q2 2026 earnings call, following the company's presentation of its quarterly results and commentary to investors.
Why it matters — The Q2 2026 earnings call transcript offers SNWV watchers direct access to management's discussion of the company's recent performance and outlook.
Sanuwave Health reported Q2 2026 revenue of $9.7 million, down 3% from $10.1 million a year earlier. The decline was driven by lower UltraMIST system sales, which offset continued growth in the company's recurring applicator business.
Why it matters — A revenue decline despite growth in the recurring applicator segment highlights ongoing challenges in the company's product mix and top-line performance.
Sanuwave announced its Q2 FY2026 financial results, reporting revenues of $9.7 million, down 3% from $10.1 million in Q2 2025. Gross margin for the quarter was 76.2%, compared to 78.1% in the prior-year quarter.
Why it matters — These results provide the latest revenue and profitability figures for Sanuwave, showing a slight year-over-year decline in both revenue and gross margin that SNWV watchers would track.
Sanuwave Health, Inc. announced it will host a conference call on August 7, 2026, at 8:30 AM ET to present its second-quarter 2026 financial results.
Why it matters — The call will provide investors and stakeholders with the company's latest quarterly financial performance and business update.
Of the 1 analysts covering SANUWAVE Health, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SANUWAVE Health, Inc. 51 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, SANUWAVE Health, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (100 of 100).
No analyst covering SANUWAVE Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SNWV are extrapolating price history, which says nothing about the business.
SANUWAVE Health, Inc. returned -88.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Sanuwave Health Inc. is an innovative company within the medical technology sector, focusing primarily on the development and commercialization of non-invasive, shockwave-based devices for a variety of medical conditions.
The most recent item we track (Seeking Alpha, 7 Aug 2026): "SANUWAVE Health, Inc. (SNWV) Q2 2026 Earnings Call Transcript". Seeking Alpha published the transcript of SANUWAVE Health, Inc.'s Q2 2026 earnings call, following the company's presentation of its quarterly results and commentary to investors.
Sanuwave Health Inc. is an innovative company within the medical technology sector, focusing primarily on the development and commercialization of non-invasive, shockwave-based devices for a variety of medical conditions. The company's flagship products are designed to promote healing in soft tissue and bone through its proprietary, high-energy, and low-energy pressure waves. These devices find applications in wound healing, particularly in chronic and diabetic ulcers, as well as in orthopedic conditions, broadening their reach across healthcare markets. Sanuwave Health Inc.'s technologies hold significance for improving patient outcomes, reducing healing times, and minimizing the need for more invasive procedures. Headquartered in Alpharetta, Georgia, the company continues to impact the medical industry by driving advancements in regenerative medicine solutions through its innovative approaches.
CEO Mr. Morgan C. Frank · 55 employees · United States · https://sanuwave.com